Get started

Pharmaceuticals

Biotech primed for a move higher?This one is almost pure intuition. We're in pharmaceuticals earnings season now. Seagen reports after market today. A bunch of other large holdings of XBI report on November 3-4, and a bunch more on November 8. Bonds and tech stocks have made a breakout move upward, and small caps look primed. (XBI is full of small and micro caps.) XBI has had a long consolidation here, and I really like the price action on it today. A lot of other sector funds have had mid-day pullbacks, but XBI has maintained its steady upward slope. It has poked above the 20-day EMA. My guess is that this will be green again tomorrow, so I've rolled the dice on a call expiring October 29. I'm also looking for continuation the next two weeks, with a first target of about 131.75.
AMEX:XBILong
by ChristopherCarrollSmith
17
MERCK GOOD OPPORTUNITY Merck & Co., Inc., d.b.a. Merck Sharp & Dohme outside the United States and Canada, is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668. Merck & Co. was established as an American affiliate in 1891 Entry on the bullish break of the dynamic trendine or on exceeding the weekly maximum. Excellent operation with a risk / return ratio of 1.20
NYSE:MRKLong
by UnknownUnicorn25541012
Vertex, a great pharmaceutical at a discounted priceA company with over 10 years of consistent and constant growth, a wide coverage of products already on the market and... despite an excellent quarterly for a news or a trail .. boom .. It drops suddenly ? In my opinion this is sheer market madness, the sites I use as a reference for fundamental analysis confirm to me what I say, the company always be more than 50% below its fair value. To confirm my conviction is also Market Miracle the algorithmic advisor, which has provided an entry signal on the stock at the price of 188 usd, also providing a valuable indication ... that is, that the price of the stock is in the area of oversold. In the immediate I don’t expect a great climb but given the solidity of the company is definitely a low-risk investment that, given the discounted price can also lead to very interesting gains in the medium term ... obviously if the price starts to rise. So I decided to increase the positions on Vertex Pharmaceuticals $VRTX hoping to be on the side of the market that as you know always has the reason on its side. This idea is based on a signal generated by the advisor Marketmiracle, down on this page you will find the link to the page of signals of the advisor that you can see for free without any cost or registration
NASDAQ:VRTXLong
by MarketMiracleAdvisor
Are we close to observe a breakout on NVAX ?Novavax COVID-19 vaccine more than 90% effective in U.S trial according to Reuters. Despite positive news (which we do not trade), we will share with you our current view on Novavax. a) The price is inside a descending Wedge, and due to positive news, we are observing a bullish GAP, and we may see the price outside the Wedge pattern b) The general strategy we will use to develop bullish setups on the pharmaceutical company is waiting for the price to reach 250 - 270 and then an ABC corrective pattern, as you can see on the chart. c) IF that scenario happens, we will trade above B, and our stop loss will be set below C d) Regarding the targets, we will be using the Fibo Extensions of the major descending wedge Thanks for reading!
NASDAQ:NVAXLong
by ThinkingAntsOk
5
PIRS - To the $4 💰-The company said that it has reached into a multi-program research collaboration and license agreement with Genentech, a member of the Roche Group, to discover, develop and commercialize locally delivered respiratory and ophthalmology therapies that leverage Pieris’ proprietary Anticalin® technology. -PIRS went on to explain that the collaboration will enable it to combine its robust discovery engine with Genentech’s targets, as well as its preclinical and clinical development expertise. As a result, the two will work together to create novel therapies for the treatment of respiratory and other ophthalmological diseases. -Importantly, these two focus areas of the collaboration are uniquely suited to the advantages offered by the small size of Anticalin proteins when delivered locally. -Under the terms of the agreement, Pieris will receive $20 million as an upfront payment and may be eligible to receive more than $1.4 billion in additional milestone payments across multiple programs, as well as tiered royalties for commercialized programs. -In exchange, PIRS will be responsible for the discovery and early preclinical development of the programs. Genentech will be responsible for IND-enabling activities, clinical development, and commercialization of the programs. Moreover, Genentech will have the option to select additional targets in return for an option exercise fee. -This news is huge! First and foremost, entering into a partnership with a company the size of Genentech comes with several advantages. Not to mention, the funding offered through this partnership will help to bolster Pieris Pharmaceuticals’ balance sheet. -At the same time, none of the internal programs at the company are included in the partnership, meaning that everything that comes out of this collaboration will be a new revenue opportunity.
PLong
by caldooninvestment
12